Unknown

Dataset Information

0

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment.


ABSTRACT: Liraglutide has pleiotropic effects favouring cardiovascular and renal risks. We investigated individual responses to liraglutide in six cardio-renal risk factors to examine whether responses in one risk factor are associated with changes in other risk factors (cross-dependency). We performed secondary analysis of the LIRA-RENAL trial (n = 279) in type 2 diabetes. HbA1c, body weight, systolic blood pressure (SBP), low density lipoprotein (LDL)-cholesterol, urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) were measured at baseline and after 26 weeks of liraglutide/placebo treatment: "Good responders" had a change within the best quartile. In the liraglutide-treated group, good HbA1c responders showed similar changes in other risk factors analysed to low responders (P ≥ 0.17). Good body weight responders had a larger reduction in HbA1c than low body weight responders (-1.6 ± 0.94 vs. -1.0 ± 0.82%; P = 0.003), but similar changes in the other risk factors (P ≥ 0.11). Good and low responders in SBP, UACR, LDL-cholesterol or eGFR showed similar changes in other risk factors (P ≥ 0.07). Treatment response to liraglutide is largely individual; aside from an association between body weight and HbA1c reduction, there are no obvious cross-dependencies in risk factor response.

SUBMITTER: Zobel EH 

PROVIDER: S-EPMC6593738 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment.

Zobel Emilie H EH   von Scholten Bernt J BJ   Goldman Bryan B   Persson Frederik F   Hansen Tine W TW   Rossing Peter P  

Diabetes, obesity & metabolism 20190222 5


Liraglutide has pleiotropic effects favouring cardiovascular and renal risks. We investigated individual responses to liraglutide in six cardio-renal risk factors to examine whether responses in one risk factor are associated with changes in other risk factors (cross-dependency). We performed secondary analysis of the LIRA-RENAL trial (n = 279) in type 2 diabetes. HbA1c, body weight, systolic blood pressure (SBP)<sub>,</sub> low density lipoprotein (LDL)-cholesterol, urine albumin-to-creatinine  ...[more]

Similar Datasets

| S-EPMC4288982 | biostudies-literature
| S-EPMC5014790 | biostudies-literature
| S-EPMC4168221 | biostudies-literature
| S-EPMC4894076 | biostudies-literature
| S-EPMC3795009 | biostudies-literature
| S-EPMC11555252 | biostudies-literature
| S-EPMC9956006 | biostudies-literature
| S-EPMC6175614 | biostudies-literature
| S-EPMC4985288 | biostudies-literature
| S-EPMC6282564 | biostudies-literature